This page shows the latest Kisqali news and features for those working in and with pharma, biotech and healthcare.
It also has plans to expand wet AMD therapy Beovu(brolucizumab-dbll) and HER-2 breast cancer treatments Piqray (alpelisib) and Kisqali(ribociclib) into additional indications to help drive growth.
However, shortly after the top-line data were announced, Novartis reported results with a trial of its rival CDK4/6 inhibitor Kisqali (ribociclib) which stole some of Lilly’s thunder. ... Results from the MONALEESA-3 in post-menopausal women with
from new prostate cancer therapy Lutathera, Kisqali (ribociclib) for breast cancer and CAR-T Kymriah (tisagenlecleucel).
Drug must prove its value via managed access route. Novartis’ Kisqali has been recommended for use on the Cancer Drugs Fund (CDF) for second line use in combination with fulvestrant in ... Ibrance and Kisqali gained NICE approval for first line
The CDK 4/6 inhibitor looks set to remain one of Pfizer’s biggest growth brands – despite competition from rival products such as Lilly’s Verzenio (abemaciclib) and Kisqali (ribociclib) from
treatments Lutathera ($106m), Promacta ($307m), Kisqali ($91m) and Kymriah ($45m).
More from news
Approximately 7 fully matching, plus 24 partially matching documents found.
Valid Insight is an award-winning pharmaceutical global market access consultancy....